Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report
Received date: 2020-07-28
Online published: 2020-12-13
禹琛 , 李春 , 范洋溢 , 徐燕 . 白塞综合征合并急性格林巴利综合征1例[J]. 北京大学学报(医学版), 2020 , 52(6) : 1146 -1149 . DOI: 10.19723/j.issn.1671-167X.2020.06.027
A 40-year-old male patient was referred to our department with complains of recurrent oral ulcer for more than 20 years and vulvar ulcer for more than 10 years. He presented with a 3-month history of right external ophthalmoplegia. More than 10 days ago, the patient received ganglioside infusion. And one week ago, he developed numbness and pain of his lambs, and progressive myasthenia, accompanied by right blepharoptosis and dysuria. On exam, motor strength was graded 0/5 in the lower and the upper extremities. Deep tendon reflexes were diminished in extremities. His admission medical examination: hemoglobin (HGB), white cell and platelet counts were normal. C-reactive protein (CRP) was negative. Erythrocyte sedimentation rate (ESR) 53 mm/h. Antinuclear antibody (ANA), anti-dsDNA antibody, anti-Smith antibody, anti-cardiolipin antibody and human leucocyte antigen B51 were all within normal range. The etiological tests of influenza A pathogen, influenza B pathogen, parainfluenza virus, enterovirus and parvovirus were all negative. He tested positive for serum anti-GM1 IgG. Cerebrospinal fluid had a normal white cell count, an elevated protein content. Gram staining, culture and PCR detection for varicella-zoster virus, cytomegalovirus and herpes simplex virus were all negative. Antibodies associated with autoimmune encephalitis and paraneoplastic syndrome were negative in cerebrospinal fluid. Electromyography and nerve conduction studies showed a severe axonal damage affecting motor nerves. No obvious abnormalities were observed in his magnetic resonance imaging of brain and cavernous sinus. The patient was diagnosed with Behcet syndrome complicated with acute Guillain-Barré syndrome. He received intravenous methylprednisolone, intravenous immunoglobulin (IVIg) therapy, plasma exchange and rituximab treatment. After treatment, the patient’s muscle strength of limbs was restored to grade 1, blepharoptosis and pain disappeared. The nervous system involvement of Behcet syndrome is relatively rare, especially combined with Guillain-Barré syndrome, which is easy to cause misdiagnosis. The treatment of Behcet syndrome complicated with acute Guillain-Barré syndrome includes the treatment of primary disease, plasma exchange and IVIg therapy. In addition, supportive treatment is very important for such patients. The focus of treatment is to avoid respiratory insufficiency, prevent deep vein thrombosis, monitor cardiac function and hemodynamics. Pain-relieving, physical exercise and psychological support are often under-recognized. The rehabilitation treatment is very important to improve the prognosis and quality of life of patients. What we need to learn is that when the symptoms and signs of the nervous system are difficult to be explained by neuro-Behcet syndrome alone, we should be alert to the possibility of other nervous system diseases.
Key words: Behcet syndrome; Guillain-Barré syndrome; Case reports; Immunoglobulins; intravenous
| [1] | Borhani-Haghighi A, Kardeh B, Banerjee S, et al. Neuro-Behcet’s disease: An update on diagnosis, differential diagnoses, and treatment[J]. Mult Scler Relat Disord, 2019,39:101906. |
| [2] | Al-Araji A, Kidd DP. Neuro-Beh?et’s disease: epidemiology, clinical characteristics, and management[J]. Lancet Neurol, 2009,8(2):192-204. |
| [3] | Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Beh?et’s disease: international consensus recommendations[J]. J Neurol, 2014,261(9):1662-1676. |
| [4] | 雷涛, 李正仪, 刘轩, 等. 眼外肌麻痹患者257例的临床特征及病因分析[J]. 中华临床医师杂志: 电子版, 2013,7(23):128-131. |
| [5] | Shugaiv E, Kiyat-Atamer A, Tüzün E, et al. Coexistence of Guillain-Barré syndrome and Beh?et’s disease[J]. Clin Exp Rheumatol, 2013,31(3 Suppl 77):88-89. |
| [6] | Nadri Q, Althaf MM. Guillian-Barré syndrome as the initial presentation of systemic lupus erythematosus: case report and review of literature[J]. Ann Saudi Med, 2015,35(3):263-265. |
| [7] | Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome[J]. Lancet, 2016,388(10045):717-727. |
| [8] | Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis[J]. Neuroepidemiology, 2011,36(2):123-133. |
| [9] | Yanaka S, Yogo R, Watanabe H, et al. On-membrane dynamic interplay between anti-GM1 IgG antibodies and complement component C1q[J]. Int J Mol Sci, 2019,21(1):147. |
| [10] | Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update[J]. Clin Neurophysiol, 2012,123(8):1487-1495. |
| [11] | 雷海波, 龙靓, 李荣辉, 等. 静脉注射神经节苷脂致格林巴利综合征文献的回顾分析[J]. 中国临床药学杂志, 2016,25(4):233-236. |
| [12] | 罗少成, 周玉兰, 王欣. 神经节苷脂相关性格林-巴利综合征的研究进展[J]. 中国城乡企业卫生, 2019,34(7):73-75. |
| [13] | Govoni V, Granieri E, Manconi M, et al. Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy[J]. J Neurol Sci, 2003,216(1):99-103. |
| [14] | Kusunoki S, Kaida K, Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: new aspects of research[J]. Biochim Biophys Acta, 2008,1780(3):441-444. |
| [15] | Zhang L, Fang Y, Cheng X, et al. Curcumin exerts effects on the pathophysiology of Alzheimer’s disease by regulating PI(3,5)P2 and transient receptor potential mucolipin-1 expression[J]. Front Neurol, 2017,8:531. |
| [16] | Maclsaac J, Siddiqui R, Jamula E, et al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin[J]. Transfusion, 2018,58(11):2729-2735. |
| [17] | Motamed-Gorji N, Matin N, Tabatabaie O, et al. Biological drugs in Guillain-Barré syndrome: An update[J]. Curr Neuropharmacol, 2017,15(7):938-950. |
| [18] | van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis[J]. Nat Rev Neurol, 2014,10(8):469-482. |
/
| 〈 |
|
〉 |